Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

被引:14
作者
Freudenburg-de Graaf, W. [1 ,2 ]
Knol, M. J. [3 ]
van der Ende, A. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, Bilthoven, Netherlands
基金
英国惠康基金;
关键词
Neisseria meningitidis; 4CMenB vaccine; Whole-genome sequencing; gMATS; B VACCINE; BACTERICIDAL ANTIBODIES; PERSISTENCE; AGE; IMMUNOGENICITY; IMMUNIZATION; ADOLESCENTS; INFANTS; STRAIN;
D O I
10.1016/j.vaccine.2020.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10(5) inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/10(5) inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to ccl 1. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:7850 / 7857
页数:8
相关论文
共 50 条
  • [21] A new multicomponent vaccine (4CMenB) to protect against serogroup B invasive meningococcal disease. Part 1: Clinical data on the immunogenicity
    Zwiauer, K. F. M.
    Broker, M.
    Banzhoff, A.
    PADIATRIE UND PADOLOGIE, 2014, 49 : 3 - 12
  • [22] 4CMenB Vaccination to Prevent Meningococcal B Disease in Vietnam: Expert Review and Opinion
    Nguyen, Phung Nguyen The
    Thai, Pham Quang
    Dien, Tran Minh
    Hai, Do Thien
    Dai, Vo Thi Trang
    Luan, Nguyen Huy
    Mathur, Gaurav
    Badur, Selim
    Truyen, Doan Minh
    Le Minh, Nguyen Hoan
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (03) : 423 - 437
  • [23] Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada
    De Serres, Gaston
    Billard, Marie-Noelle
    Gariepy, Marie-Claude
    Rouleau, Isabelle
    Toth, Eveline
    Landry, Monique
    Boulianne, Nicole
    Gagne, Helene
    Gilca, Vladimir
    Deceuninck, Genevieve
    Ouakki, Manale
    Skowronski, Danuta M.
    VACCINE, 2018, 36 (52) : 8039 - 8046
  • [24] Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
    Scholz, Stefan
    Schwarz, Magdalena
    Beck, Ekkehard
    Meszaros, Kinga
    Schneider, Melanie
    Ultsch, Bernhard
    Greiner, Wolfgang
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 367 - 387
  • [25] Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England
    Beck, Ekkehard
    Klint, Johan
    Garcia, Stephanie
    Abbing, Victoria
    Abitbol, Veronique
    Akerborg, Orjan
    Argante, Lorenzo
    Bekkat-Berkani, Rafik
    Hogea, Cosmina
    Neine, Mohamed
    Vadivelu, Kumaran
    Whelan, Jane
    Meszaros, Kinga
    VACCINE, 2020, 38 (47) : 7558 - 7568
  • [26] Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020
    Muzzi, Alessandro
    Lu, Min-Chi
    Mori, Elena
    Biolchi, Alessia
    Fu, Tiffany
    Serino, Laura
    MSPHERE, 2024, 9 (06)
  • [27] Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives
    Whelan, Jane
    Bambini, Stefania
    Biolchi, Alessia
    Brunelli, Brunella
    Holle, Mirna Robert-Du Ry van Beest
    EXPERT REVIEW OF VACCINES, 2015, 14 (05) : 713 - 736
  • [28] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    O'Ryan, Miguel
    Stoddard, Jeffrey
    Toneatto, Daniela
    Wassil, James
    Dull, Peter M.
    DRUGS, 2014, 74 (01) : 15 - 30
  • [29] A new multicomponent vaccine (4CMenB) to protect against serogroup B meningococcal disease. Part 2: Safety and tolerability
    Zwiauer, K. F. M.
    BrOKer, M.
    Banzhoff, A.
    PADIATRIE UND PADOLOGIE, 2014, 49 : 13 - 19
  • [30] Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland
    Mulhall, Robert M.
    Bennett, Desiree
    Cunney, Robert
    Borrow, Ray
    Lucidarme, Jay
    Findlow, Jamie
    Jolley, Keith A.
    Bray, James
    Maiden, Martin C. J.
    Moschioni, Monica
    Serino, Laura
    Stella, Maria
    Medini, Duccio
    MSPHERE, 2018, 3 (04):